Tirzepatide vs Semaglutide
Tirzepatide vs Semaglutide: mechanism, evidence, and cost
How tirzepatide and semaglutide compare on mechanism, weight-loss evidence, oral options, CV data, and compounded cost.
Tirzepatide and Semaglutide are different molecules: Tirzepatide is a dual GIP and GLP-1 receptor agonist, while Semaglutide is a single GLP-1 receptor agonist. In head-to-head and cross-trial terms, tirzepatide has produced larger average weight loss (~20.9% in SURMOUNT-1) than semaglutide (~14.9% in STEP 1), while semaglutide has the additional SELECT cardiovascular outcome evidence and an approved oral form. Compounded versions of either are not FDA approved.
If you are specifically considering tirzepatide
If you are weighing tirzepatide specifically, its distinguishing strength is magnitude: the dual GIP/GLP-1 mechanism produced the highest average weight loss in trials (~20.9% in SURMOUNT-1), and Zepbound now carries an obstructive sleep apnea indication. Some people who plateaued on a single GLP-1 agonist consider the dual mechanism next. The trade-offs are a higher compounded price, a shorter track record, and no approved oral option — so the choice is peak effect and newer evidence versus breadth and cost.
For people who have already plateaued on a single GLP-1 agonist, the dual GIP/GLP-1 mechanism is the specific reason tirzepatide is considered next; the second incretin pathway is what distinguishes it pharmacologically. That rationale applies to the approved product at studied doses — not to a compounded tirzepatide microdose, which has no such comparative evidence.
Head-to-head on the facts
| Dimension | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | Single GLP-1 agonist | Dual GIP + GLP-1 agonist |
| Headline weight loss | ~14.9% (STEP 1) | ~20.9% (SURMOUNT-1) |
| Approved oral form | Yes (Rybelsus, diabetes) | No |
| CV outcome trial | SELECT (~20% MACE reduction) | Not established for weight indication |
| Compounded cost (NexLife 12-mo) | $145/mo | $186/mo |
| Brands | Wegovy / Ozempic / Rybelsus | Zepbound / Mounjaro |
Headline mean weight loss, approved products (%) — different trials and populations — not a head-to-head RCT of these exact figures
How to choose (with a clinician)
The larger average weight loss with tirzepatide is real but comes from a different trial and population, so the percentages are not a perfectly matched head-to-head. Semaglutide's cardiovascular outcome data and approved oral option matter for some people. Tolerability, cost, and medical history often decide it in practice — which is a conversation for a prescriber, not a checkout page.
What the evidence shows
- Both molecules produce clinically meaningful weight loss at approved doses.
- Tirzepatide's average weight loss is higher across trials; semaglutide has SELECT CV evidence.
What the evidence does not show
- That the cross-trial percentages equal a head-to-head RCT result.
- That compounded versions of either share the approved evidence.
Frequently asked questions
Which is better for weight loss, semaglutide or tirzepatide?
On average, tirzepatide produced more weight loss (~20.9%) than semaglutide (~14.9%), but in different trials. Choice depends on medical history, tolerability, and cost.
Is one cheaper when compounded?
Compounded semaglutide is generally cheaper than tirzepatide; at NexLife, $145/mo vs $186/mo standard at the 12-month tier.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.